Filing Analysis
Viemed Healthcare, Inc. filed an 8-K to provide an updated Investor Deck Presentation (Exhibit 99.1) for use in communications with investors and analysts.
📋 Key Facts
- The filing is a Regulation FD disclosure (Item 7.01).
- The company is providing an updated 'Investor Deck Presentation' dated August 2026 (Exhibit 99.1).
- The presentation is intended for use in meetings with investors, analysts, and other third parties.
- The information in the presentation is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Viemed Healthcare, Inc. filed an 8-K to announce its quarterly financial results for the three and six months ended June 30, 2026. The filing includes a press release and a financial supplement as exhibits.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2026.
- Filing date: August 3, 2026.
- The company issued a Press Release (Exhibit 99.1) regarding financial results.
- The company issued a Financial Supplement (Exhibit 99.2) regarding financial results.
Viemed Healthcare, Inc. entered into a Third Amendment to its existing Credit Agreement with Regions Bank. The amendment primarily extends the expiration date of the Borrower's delayed draw term loan commitment by one year.
🚩 Red Flags
- The extension of a delayed draw term loan commitment suggests the company is securing additional liquidity runway, which can sometimes indicate a need for more flexible capital access.
📋 Key Facts
- Entered into a Third Amendment to the Credit Agreement dated November 29, 2022, on November 7, 2025.
- The amendment extends the delayed draw term loan commitment expiration date from November 29, 2025, to November 29, 2026.
- Includes other technical amendments to the existing agreement.
- The company released an updated Investor Deck Presentation (Exhibit 99.1).
Viemed Healthcare, Inc. issued an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via press release and supplemental data.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2025.
- Filing date: November 5, 2025.
- The company released a formal Press Release (Exhibit 99.1) and a Financial Supplement (Exhibit 99.2).
- The filing was signed by CFO Trae Fitzgerald.
Viemed Healthcare, Inc. announced the completion of its previously authorized share repurchase program on September 23, 2025.
📋 Key Facts
- Completed all repurchases under the previously announced share repurchase program.
- Total common shares repurchased: 1,976,441 shares.
- Aggregate purchase price: approximately $13.2 million (before applicable taxes).
- Announcement date: September 23, 2025.
Viemed Healthcare, Inc. issued an 8-K to announce its financial results for the three and six months ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via press release and supplemental financial data.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2025.
- Filing date: August 6, 2025.
- The filing includes a Press Release (Exhibit 99.1) and a Financial Supplement (Exhibit 99.2).
- Information is provided under General Instruction B.2 to limit liability under Section 18 of the Exchange Act.
Viemed Healthcare, Inc. has completed the acquisition of Lehan’s Medical Equipment for a base price of $26 million plus contingent consideration. The company expects to update its 2025 full-year guidance following this transaction.
🚩 Red Flags
- Contingent consideration ($2.2M) introduces potential future liability/expense depending on performance metrics.
📋 Key Facts
- Acquisition of Lehan's Medical Equipment, a private home medical equipment provider based in DeKalb, Illinois.
- Base purchase price is $26 million, subject to customary adjustments.
- Estimated contingent consideration (earn-out) of approximately $2.2 million.
- Company anticipates updating full-year 2025 guidance upon reporting Q2 2025 earnings.
Viemed Healthcare, Inc. has amended its existing credit agreement to increase the permitted amount of restricted payments and authorized a new share repurchase program through June 2026.
🚩 Red Flags
- Increased capacity for restricted payments (share repurchases) can sometimes indicate a priority on returning capital over reinvestment in growth, though this is context-dependent.
📋 Key Facts
- Entered into a Second Amendment to the Credit Agreement dated November 29, 2022, on June 6, 2025.
- The amendment increases the permitted amount of restricted payments available to the Company and its subsidiaries.
- Board of Directors authorized a share repurchase program effective through June 2026.
- The company may repurchase up to 1,976,441 common shares via open market or block purchases.
Viemed Healthcare held its Annual General and Special Meeting of Shareholders on June 5, 2025. The meeting resulted in the election of seven directors, the appointment of Ernst & Young LLP as independent auditors for FY2025, and approval of an amendment to the 2024 Long Term Incentive Plan (LTIP).
📋 Key Facts
- Shareholders approved an amendment to the 2024 LTIP increasing the maximum number of common shares available for issuance.
- The LTIP amendment clarifies vesting treatment in change-in-control events and establishes a minimum one-year vesting period.
- Seven directors were elected, including Casey Hoyt (96.64% for) and W. Todd Zehnder (96.02% for).
- Ernst & Young LLP was appointed as independent auditors for the fiscal year ending December 31, 2025.
- Shareholders approved a non-binding advisory vote on executive compensation ('say-on-pay') with 97.85% approval.
- Shareholders voted to hold future 'say-on-pay' votes on an annual (1 year) basis.
Viemed Healthcare, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing includes a press release and a financial supplement detailing the company's quarterly performance.
📋 Key Facts
- The filing reports financial results for the three months ended March 31, 2025.
- The announcement was made on May 7, 2025.
- Exhibits 99.1 (Press Release) and 99.2 (Financial Supplement) were provided to detail the results.
Viemed Healthcare, Inc. has entered into a definitive agreement to acquire Lehan Drugs, Inc., a private home medical equipment provider, for an estimated $28.2 million including contingent payments.
🚩 Red Flags
- Contingent payments ($2.2M) introduce potential future liabilities and uncertainty regarding final deal value.
📋 Key Facts
- Acquisition of Lehan Drugs, Inc., a privately held home medical equipment provider based in DeKalb, Illinois.
- Base purchase price is $26 million.
- Potential additional $2.2 million in contingent payments (earn-outs).
- Transaction subject to customary net working capital adjustments.
- Expected closing date: Third quarter of 2025.
Viemed Healthcare, Inc. announced the immediate resignation of Bruce Greenstein from its Board of Directors on April 14, 2025. Mr. Greenstein served as Chairman of the Corporate Governance & Nominating Committee and was a member of the Audit Committee.
🚩 Red Flags
- Departure of an Audit Committee member can sometimes precede internal scrutiny, though no disagreement was noted here.
📋 Key Facts
- Bruce Greenstein resigned from the Board of Directors effective April 14, 2025.
- Mr. Greenstein held roles as Chairman of the Corporate Governance & Nominating Committee and as a member of the Audit Committee.
- The company explicitly stated that the resignation was not due to any disagreement with the Company or its Board regarding operations, policies, or practices.
Viemed Healthcare, Inc. filed an 8-K to provide a new Investor Deck Presentation under Regulation FD disclosure rules. This is a routine filing used to update the company's investor relations materials.
📋 Key Facts
- The company released an updated 'Investor Deck Presentation' (Exhibit 99.1) on March 18, 2025.
- The presentation is intended for use in communications with investors and analysts.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 liability.
Viemed Healthcare, Inc. filed an 8-K to announce its financial results for the three months and fiscal year ended December 31, 2024.
📋 Key Facts
- The filing is a standard earnings release announcement dated March 10, 2025.
- Covers financial performance for the period ending December 31, 2024.
- Includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Financial Supplement).
Viemed Healthcare, Inc. has filed an 8-K to disclose the use of a new Investor Deck Presentation (Exhibit 99.1) for upcoming presentations to investors and analysts.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The company intends to use the attached 'Investor Deck Presentation November 2024' in connection with investor/analyst meetings.
- The presentation is intended as summary information and not a formal update to SEC filings unless specifically stated.
Viemed Healthcare, Inc. issued an 8-K to announce its financial results for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is an emerging growth company.
Viemed Healthcare, Inc. filed an 8-K to provide an updated Investor Deck Presentation under Regulation FD. This is a routine disclosure intended for use in meetings with investors and analysts.
📋 Key Facts
- The filing includes an 'Investor Deck Presentation' as Exhibit 99.1 dated August 2024.
- The information provided is summary information intended to be viewed alongside official SEC filings.
- The company explicitly states the presentation is not considered 'filed' for purposes of Section 18 liability under the Exchange Act.
Viemed Healthcare, Inc. issued an 8-K to announce its financial results for the three and six months ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly/semi-annual financial results (Item 2.02).
- Reporting period covers the three and six months ended June 30, 2024.
- The company is an emerging growth company as defined in Rule 405 of the Securities Act.
Viemed Healthcare held its Annual & Special Meeting of Shareholders on June 6, 2024. The meeting resulted in the election of eight directors and the approval of Ernst & Young LLP as auditors for the 2024 fiscal year.
🚩 Red Flags
- Significant opposition to the Long Term Incentive Plan (30.79% against) and certain directors (e.g., Bruce Greenstein at 18.61% withheld/against).
📋 Key Facts
- Annual & Special Meeting of Shareholders held on June 6, 2024.
- Eight nominees were elected to the Board of Directors with varying levels of support (ranging from 81.39% to 98.56%).
- Ernst & Young LLP was appointed as auditors for the fiscal year ending December 31, 2024, receiving 99.67% approval.
- The 2024 Long Term Incentive Plan was ratified by shareholders with 69.21% of votes in favor.
Viemed Healthcare, Inc. entered into a First Amendment to its existing Credit Agreement on May 28, 2024. The amendment primarily extends the expiration date of the Borrower's delayed draw term loan commitment.
🚩 Red Flags
- The extension of a delayed draw term loan commitment expiration date suggests the company was approaching a deadline for accessing additional liquidity, which can be a sign of tight cash management or reliance on external financing to maintain operations.
📋 Key Facts
- The First Amendment was executed on May 28, 2024.
- The amendment extends the delayed draw term loan commitment expiration date from May 29, 2024, to November 29, 2025.
- The original Credit Agreement is dated November 29, 2022.
- Regions Bank serves as the administrative agent and collateral agent.
Viemed Healthcare, Inc. filed an 8-K to provide a new investor presentation (Exhibit 99.1) intended for use in communications with investors and analysts.
📋 Key Facts
- The filing includes an updated 'Investor Deck Presentation May 2024' as Exhibit 99.1.
- The information is provided under Item 7.01 (Regulation FD Disclosure).
- The presentation is intended for use in investor and analyst meetings and is available on the company website.
Viemed Healthcare, Inc. issued an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of the quarterly earnings press release.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Three months ended March 31, 2024
- The company is an emerging growth company
- Financial results were released via press release (Exhibit 99.1)
Viemed Healthcare, Inc. has finalized a strategic partnership with East Alabama Health, resulting in the Company acquiring a controlling interest in East Alabama HomeMed, LLC.
📋 Key Facts
- Strategic partnership finalized on April 2, 2024.
- The agreement grants Viemed Healthcare a controlling interest in East Alabama HomeMed, LLC.
- Partnership is with East Alabama Health.
Viemed Healthcare, Inc. filed an 8-K to provide a new investor presentation (Exhibit 99.1) intended for use in communications with investors and analysts.
📋 Key Facts
- The filing includes an 'Investor Deck Presentation' dated March 2024 as Exhibit 99.1.
- The company intends to use this deck for presentations to investors, analysts, and other parties.
- Information in the presentation is intended to be viewed in context with SEC filings.
Viemed Healthcare, Inc. issued an 8-K to announce its financial results for the three months and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 6, 2024
- Reporting period covered: Three months and full year ended December 31, 2023
- The filing consists of a press release (Exhibit 99.1) announcing financial results
- Company is an emerging growth company